News
Johnson & Johnson shrugs off tariff impact and forecasts sales boost
Johnson & Johnson has shrugged off the impact of tariffs as the US-based healthcare group raised its earnings and sales guidance for 2025. J&J, which warned of $400mn in duty costs following President Donald Trump’s “liberation day” tariffs announcement in April,
Johnson & Johnson lifts 2025 forecast, halves tariff cost outlook
Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and profit forecast on Wednesday after a strong quarter for flagship cancer drug Darzalex and its cardiovascular devices.
2don MSN
The healthcare company's payout currently yields 3.3%, more than double the S&P 500 's ( ^GSPC 0.32%) dividend yield (near a ...
Johnson & Johnson shares fell slightly Thursday after soaring yesterday amid investor optimism about the company's ...
CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Johnson & Johnson (NYSE:JNJ) has long been considered one of the most dependable dividend stocks, ...
Since announcing his defection to LIV in 2022, Johnson’s slippage in the sport has been somewhat of an unspoken tragedy.
The talking point, as of late, stemming from the 2025 NFL Draft, was why second-round picks weren't signing. As of a few days ...
The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...
SB Nation on MSN11h
Nolan Smith credits Lane Johnson for his big leap in Year 2 with the EaglesAhead of his third season, Eagles edge rusher Nolan Smith spoke to his teammates Cooper DeJean and Reed Blankenship on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback